KRAS G12F

Clinical trials for KRAS G12F explained in plain language.

Never miss a new study

Get alerted when new KRAS G12F trials appear

Sign up with your email to follow new studies for KRAS G12F, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill targets 'Undruggable' cancer mutations in major trial

Disease control Recruiting now

This study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …

Matched conditions: KRAS G12F

Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

KRAS G12F

Get alerted when new KRAS G12F trials appear

New pill targets 'Undruggable' cancer mutations in major trial